Comparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccines

Basit Öğe Kaydı
dc.authorid0000-0002-6833-5646en_US
dc.authorid0009-0001-8675-879Xen_US
dc.authorscopusid6507971898en_US
dc.authorscopusid55929862900en_US
dc.authorwosidC-7080-2019en_US
dc.authorwosidFQL-2525-2022en_US
dc.contributor.authorAtıcı, Serkan
dc.contributor.authorSoysal, Ahmet
dc.contributor.authorGönüllü, Erdem
dc.contributor.authorAydemir, Gökhan
dc.contributor.authorÖner, Cevat Naci
dc.contributor.authorAlan, Servet
dc.contributor.authorEngin, Havva
dc.contributor.authorYıldız, Melek
dc.contributor.authorKaraböcüoğlu, Metin
dc.date.accessioned2023-07-22T06:52:50Z
dc.date.available2023-07-22T06:52:50Z
dc.date.issued2023en_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractBackground: Heterologous COVID-19 booster vaccination is an alternative strategy to homologous vaccination, especially in developing countries, due to shortages, delays, or unequal distribution of COVID-19 vaccines. We compared cohorts vaccinated with different vaccine combinations to investigate whether a heterologous booster dose of mRNA-based BNT162b2 vaccine boosts the immune response in individuals primed with the CoronaVac vaccine. Methods: Anti-RBD IgG is generally measured 4 weeks after primary immunization and 4 weeks after booster vaccination. Data on anti-receptor-binding domain (anti-RBD) IgG antibody titers and clinical characteristics were provided by infection control units. Results: The highest median anti-RBD IgG antibody titers (14589 AU/mL) after primary immunization was observed in the group vaccinated with two doses of BNT162b2 vaccine. Antibody titers were lower 4 months or more after the second CoronaVac vaccine dose in CoronaVac recipients with or without previous COVID-19. In the homologous COVID-19 booster vaccine group (primed with two doses of CoronaVac 4 weeks apart and a single booster dose of CoronaVac) the median anti-RBD titers decreased from 1025 to 242 AU/mL before the booster dose. In the heterologous group (primed with two doses of CoronaVac 4 weeks apart and a single booster dose of BNT162b2), the median anti-RBD titer increased to 31624 AU/mL, a 132-fold increase, 16 days after the booster dose. Conclusions: After the second dose of CoronaVac, protective neutralizing antibody levels decrease over time, and a booster dose is required. Heterologous COVID-19 booster vaccination with BNT162b2 is effective at boosting neutralizing antibody levels.en_US
dc.identifier.citationAtıcı, S., Soysal, A., Gönüllü, E., Aydemir, G., Öner, C. N., Alan, S., Engin, H., Yıldız, M., & Karaböcüoğlu, M. (2023). Comparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccines. Journal of the Brazilian Society of Tropical Medicine, 56, pp. 1-7. https://doi.org/10.1590/0037-8682-0046-2023en_US
dc.identifier.doi10.1590/0037-8682-0046-2023en_US
dc.identifier.endpage7en_US
dc.identifier.issn0037-8682
dc.identifier.issn1678-9849
dc.identifier.pmidPMID: 37493731en_US
dc.identifier.scopus2-s2.0-85165719865en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://doi.org/10.1590/0037-8682-0046-2023
dc.identifier.urihttps://hdl.handle.net/20.500.13055/499
dc.identifier.volume56en_US
dc.identifier.wosWOS:001089394400001en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorGönüllü, Erdem
dc.institutionauthorÖner, Cevat Naci
dc.language.isoenen_US
dc.publisherSociedade Brasileira De Medicina Tropicalen_US
dc.relation.ispartofJournal of the Brazilian Society of Tropical Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOVID-19 Vaccinesen_US
dc.subjectCoronavacen_US
dc.subjectBNT162b2en_US
dc.subjectBooster Doseen_US
dc.subjectHeterologous Vaccination Scheduleen_US
dc.subjectHomologous Vaccination Scheduleen_US
dc.titleComparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccinesen_US
dc.typeArticleen_US
dspace.entity.typePublication

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
544.39 KB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu